Q1 Earnings Forecast for BTAI Issued By HC Wainwright

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for BioXcel Therapeutics in a research report issued on Monday, June 23rd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($0.69) per share for the quarter. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($24.39) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.51) EPS and Q4 2026 earnings at ($0.50) EPS.

A number of other equities analysts have also recently weighed in on the company. Wall Street Zen raised BioXcel Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 6th. RODMAN&RENSHAW upgraded shares of BioXcel Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 19th. Finally, Rodman & Renshaw began coverage on shares of BioXcel Therapeutics in a report on Wednesday, March 19th. They issued a “buy” rating and a $65.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.60.

BioXcel Therapeutics Stock Up 18.5%

Shares of BTAI stock opened at $2.05 on Tuesday. The business has a 50-day moving average price of $1.61 and a two-hundred day moving average price of $3.13. BioXcel Therapeutics has a 12-month low of $1.17 and a 12-month high of $25.12. The firm has a market cap of $12.42 million, a P/E ratio of -0.15 and a beta of -0.12.

BioXcel Therapeutics (NASDAQ:BTAI) last posted its quarterly earnings data on Monday, May 12th. The company reported ($1.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.72) by $1.22. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.35 million.

Institutional Investors Weigh In On BioXcel Therapeutics

Institutional investors have recently bought and sold shares of the stock. Squarepoint Ops LLC lifted its position in BioXcel Therapeutics by 203.9% in the fourth quarter. Squarepoint Ops LLC now owns 72,046 shares of the company’s stock valued at $27,000 after purchasing an additional 48,336 shares during the last quarter. Northern Trust Corp increased its stake in shares of BioXcel Therapeutics by 81.4% in the fourth quarter. Northern Trust Corp now owns 73,910 shares of the company’s stock worth $28,000 after buying an additional 33,161 shares during the period. Goldman Sachs Group Inc. purchased a new position in shares of BioXcel Therapeutics in the first quarter worth $50,000. Wells Fargo & Company MN raised its holdings in BioXcel Therapeutics by 7.5% during the 4th quarter. Wells Fargo & Company MN now owns 199,010 shares of the company’s stock valued at $74,000 after buying an additional 13,952 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in BioXcel Therapeutics by 4.7% during the 4th quarter. Geode Capital Management LLC now owns 311,965 shares of the company’s stock valued at $117,000 after buying an additional 13,922 shares during the last quarter. 30.68% of the stock is currently owned by hedge funds and other institutional investors.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.